Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average acquisition cost for dozens of specialty generic drugs, bringing in more than $7.

CVS Health (NYSE:CVS), Humana (NYSE:HUM), Molina Healthcare (NYSE:MOH), and UnitedHealth Group (NYSE:UNH) saw an upswing following Elevance Health's latest quarterly results. Elevance Health, formerly known as Anthem,

The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension drug.

The UnitedHealth Group is overcharging patients for necessary life-saving drugs as a result of price gouging that increases the cost of such medication exponentially.

But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it had made less than analysts expected.

UnitedHealth Group’s upcoming earnings call marks the company's first public appearance since the murder of UnitedHealthcare CEO Brian Thompson.

The year 2024 was exceptional for US stocks, with the broader market climbing over 23% and the […] (Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged ...

FTC stated that the 'Big 3' PBM organisations collectively generated over £5.94 billion ($7.3 billion) in revenue from 2017 to 2022.

Patrick T Fallon/Getty Images The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's Express Scripts—marked up prices at ...

Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.

Investing.com -- Shares of CVS Health Corp (NYSE:CVS), Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their pharmacy benefit manager units of imposing significant price ...

(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average acquisition cost for dozens of specialty generic drugs, bringing in more than $7.3 billion in “excess” revenue over ...